Media Coverage
November 2008
"Labour of Love" - Avenue magazine
A city tycoon eager to relieve his wife’s multiple sclerosis found hope in a University of Alberta lab. He added his business savvy and funding to the researchers’ skills - now the world is on the verge of getting a breakthrough drug.
2008 BioAlberta Achievement Awards
BioAlberta announced the winners of the 2008 BioAlberta Achievement Awards at its 9th Annual General Meeting and Awards Gala. The winners include 'Company of the Year' BioMS Medical Corporation.
To mark its 10th anniversary, Drug Discovery & Development magazine invited pharmaceutical and biotechnology companies to reflect on the history and made predictions about future of the industry. Featured here are verbatim comments from BioMS Medical.
October 2008
Prairies Ernst & Young Entrepreneur Of The Year 2008 Awards: Biotechnology and Technology
Recipients of the Prairies Ernst & Young Entrepreneur Of The Year 2008 Awards for Biotechnology and technology are: Clifford Giese, Kevin Giese - BioMS Medical.
September 2008
"Two Steps Forward" by Mary Ellen Egan - Forbes magazine
New drug in late-stage trials offer promise for sufferers of the chronic and crushing disease multiple sclerosis.
"The Faces of Canadian Biotech" - BioBusiness magazine
Almost 10 years and many accomplishments and accolades, including one of the largest biotechnology deals in Canadian history, most pundits in the life sciences sector would argue the company is the very definition of success.
Please note that this article may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.